Patient P-01720

Synthetic patientNBL-101 · Day 116 · 25–34 · M · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −17% vs expected — Dietary Support Protocol NP-02
Day 48 Tolerance state changed — Unstable → Improving
Day 51 Trajectory diverged from prediction — Observed response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 51.

Primary contributors, last 14 days

Inflammatory activity+18
GI instability+16
Toxicity+13
Treatment adherence+11
Nutritional resilience-9

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −17%

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 25/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 68
- WearableHRV 36 ms, trending down
Autonomic recovery ↓65
- WearableResting HR 78 bpm
- Wearable1,426 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 67 and rising
- WearableSleep 5.1 h, below personal baseline
Drug metabolism and exposure ↑20
- BloodToxicity index 58

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.3 · butyrate capacity 25/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 40 ms
Sleep: 5.5 h
Steps: 1,862
Resting HR: 77 bpm

Daily log: GI score 67, nutritional resilience 34, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01615	57%	S14	ME-01	improved	48
P-01728	51%	S14	SC-12	improved	41
P-01605	49%	S14	ME-01	improved	41
P-01656	49%	S14	ME-01	improved	41
P-01612	48%	S14	ME-01	improved	51
P-01842	48%	S14	NP-02	improved	55
P-01531	47%	S14	ME-01	improved	51
P-01716	47%	S14	GI-04	improved	56
P-01751	47%	S14	ME-01	improved	48
P-01412	46%	S14	NP-02	improved	49
P-01462	45%	S14	NP-02	improved	47
P-01692	45%	S14	NP-02	improved	49